Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
Moderate‐potency may leads to lower patient‐reported symptoms of eczema: 1‐5 weeks compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Low birthweight · pregnant women
Mild/moderate topical corticosteroids may leads to lower low birth weight compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.9
55713 participants
Low
Preterm birth · pregnant women
Mild/moderate topical corticosteroids may leads to lower preterm delivery compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.88
55713 participants
Low
Foetal death · pregnant women
Mild/moderate topical corticosteroids may leads to lower foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.7
48749 participants
Low
Low Apgar score · pregnant women
Mild/moderate topical corticosteroids may leads to lower low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.73
8756 participants
Low
Congenital abnormality · pregnant women
Mild/moderate topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.93
9263 participants
Low
Orofacial cleft · pregnant women
Mild/moderate topical corticosteroids may leads to lower orofacial cleft compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.95
38446 participants
Low
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod cream probably leads to lower pain (moderate/severe) compared with MAL‐PDT (moderate certainty).
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod showed no clear difference in pain (moderate/severe) compared with surgical excision (low certainty).
1 finding from 1 review
Participants' global self‐assessment of acne improvement Moderate to excellent improvement (long term: treatment duration > 8 weeks) · participants with acne
Salicylic acid showed no clear difference in participants' global self‐assessment of acne improvement Moderate to… compared with tretinoin (low certainty).
1 finding from 1 review
Primary outcome: adverse events (assessed at 3 months as minimum, moderate or severe) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.03% changes physician's assessment of global response of improvement, clear or… compared with corticosteroids (very low certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Twice daily or more showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with once daily topical corticosteroid (moderate certainty).
1 finding from 1 review